Panchal is set to transition to a global role within the AstraZeneca Group, based in Gaithersburg, Maryland, US. The board ...

Comparative assessments and other editorial opinions are those of U.S. News and have not been previously reviewed, approved ...

Meanwhile, Sanofi has pointed to Beyfortus’ 75% reduction in the incidence of MALRI versus Enflosia’s figure of 60%. The ...

Known as Enflonsia, the drug will compete for market share with Sanofi and AstraZeneca’s in-demand Beyfortus, which quickly ...

The U.S. Food and Drug Administration on Monday approved Merck's preventive antibody shot to protect infants up to one year ...

Merck’s shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.

In an effort to greater prepare HCPs and to avoid potential shortages, the company targets Q3 as the shipment date.

IonQ announced the acquisition of a UK rival Monday and unveiled results of a collaboration involving semiconductor titan ...

Sanofi boosts Beyfortus output for RSV season while Dupixent trial shows strong eczema relief in patients with skin of color.

Dietmar Berger, M.D., Ph.D., joined Gilead Sciences as chief medical of | Dietmar Berger became Gilead Sciences’ new chief ...

The benefits of 52-week biologic therapy on asthma control and lung function are observed in both never smokers and ...

IonQ (IONQ) announced results of a research program between the company, AstraZeneca (AZN), Amazon Web Services (AMZN) and Nvidia (NVDA).